Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.
Avalo Therapeutics, Inc. reported the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, including senior roles at Abzena and Longboard Pharmaceuticals, where he led significant M&A and licensing activity.
Under an employment agreement dated September 29, 2025, Boyd will receive a base salary of $465,000 and a discretionary annual bonus targeted at up to 40% of base salary, payable in cash or, if mutually agreed, immediately vested equity. As an inducement, he will be granted a stock option for 275,000 shares of Avalo common stock on October 1, 2025, with an exercise price equal to the Nasdaq closing price on the grant date and vesting over four years.
If Avalo terminates Boyd without Cause or he resigns for Good Reason, severance protections include continued salary for nine months (extended to 12 months if termination occurs within six months after a Change in Control), a prorated or enhanced bonus depending on timing, full vesting of outstanding options with six months to exercise, and up to 12 months of COBRA premium payments, all conditioned on a release of claims and compliance with confidentiality, non-disparagement, invention assignment, non-competition, and non-solicitation covenants.
Avalo Therapeutics, Inc. reported changes to its board of directors. The company’s board appointed Kevin Lind as a director effective October 1, 2025, and he will also join the Audit Committee, serving until the 2026 annual meeting or until a successor is elected and qualified.
In line with Avalo’s Amended and Restated Non-Employee Director Compensation Plan, Mr. Lind will receive a non-qualified stock option to purchase 40,200 shares of common stock on October 1, 2025, vesting in three equal annual installments, with an exercise price equal to that day’s Nasdaq Capital Market closing price.
June Almenoff, M.D., Ph.D. resigned as a director, effective October 1, 2025, to pursue new opportunities; her resignation, including from the Audit Committee, is stated as not related to the company’s operations, policies, or practices. Avalo is accelerating vesting of her outstanding equity awards as of October 1, 2025, and extending the expiration dates of her outstanding stock options to September 30, 2026.
Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.
Avalo Therapeutics (AVTX) disclosed that OrbiMed Advisors LLC beneficially holds 967,000 shares of common stock, representing 8.9% of the class, with shared voting and dispositive power over those shares. OrbiMed Capital GP IX LLC separately reports beneficial ownership of 644,667 shares, or 6.0% of the class, also with shared voting and dispositive power. The filing states these holdings are exercised on behalf of other persons and that the reported shares were not acquired to change or influence control of the issuer. Key executives on the management committee are identified as exercising voting power.
Form 4 overview: Avalo Therapeutics, Inc. (AVTX) filed a Form 4 disclosing an equity-based compensation grant to board member Samantha Truex on 06/17/2025. The filing reports no sales or disposals of common stock; it solely records the award of new derivative securities.
Key terms of the option grant
- Security: Stock Option (Right to Buy) on AVTX common shares
- Underlying shares: 20,100
- Exercise price: $4.47 per share
- Vesting schedule: 100 % cliff vest on the first anniversary of the grant date, conditional on Ms. Truex’s continued board service
- Expiration: 06/17/2035 (10-year term)
- Ownership form after transaction: Direct
The transaction increases Ms. Truex’s derivative beneficial ownership to 20,100 options. No non-derivative (common stock) positions are listed in this filing, and there is no indication of Rule 10b5-1 trading plan use.
Investor takeaway: The filing reflects routine board compensation rather than market activity. While the additional options further align the director’s incentives with shareholders, the relatively small size (≈20 k shares) suggests limited immediate impact on AVTX’s share float or insider-sentiment signals.